Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Monovalent inactivated influenza vaccine · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Monovalent inactivated influenza vaccine | BIOLOGICAL | Two doses of monovalent inactivated influenza adjuvanted vaccine |
Inclusion Criteria: * Subjects aged 18 to 60 years of age who are mentally competent and who have signed an informed consent form after having received a detailed explanation of the study protocol; * In good health as determined by: * Medical history, * Physical examination, * Clinical judgm...
Monovalent inactivated influenza vaccine is used as a prepandemic and pre-pandemic influenza vaccine. It is designed to protect against potential pandemic influenza virus strains, specifically targeting the H5N1 strain in clinical trials.
Monovalent inactivated influenza vaccine is being developed by Novartis AG, which trades under the ticker NVS. The vaccine is currently in Phase 3 clinical development for prepandemic influenza indications.
Monovalent inactivated influenza vaccine is in Phase 3 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. Clinical trials are ongoing to evaluate its safety and immunogenicity.
Monovalent inactivated influenza vaccine has been studied in two completed clinical trials. NCT00841646 was a Phase 2 trial with 343 participants, and NCT00848029 was a Phase 3 trial with 240 participants. Both evaluated the vaccine's safety and immunogenicity in adult and elderly subjects.
Monovalent inactivated influenza vaccine works by presenting a surface antigen from a potential pandemic virus strain candidate, H5N1, to the immune system. This antigen is adjuvanted with MF59C.1 (MF59) to enhance the immune response, helping the body develop immunity against the H5N1 strain.